Abstract:The continued efforts to evaluate biomarkers’ predictive abilities and identify optimal biomarker combinations are often challenged by the absence of a gold standard, that is, the true disease status. Current methods that address this issue are mostly developed for binary or ordinal diagnostic tests, which do not fully utilize information provided by continuous biomarkers, or require strong parametric assumptions. Moreover, limited methods exist to allow for the inclusion of covariates—despite their crucial role in facilitating the accurate evaluation of biomarkers. In this paper, we proposed a latent profile approach to evaluating diagnostic accuracy of biomarkers without a gold standard. The method allows for flexible biomarker distributions and incorporation of previous knowledge about risk factors while simultaneously permitting researchers to model paticipants’ characteristics that putatively affect biomarker levels, and therefore provides information needed to develop more personalized diagnostic procedures. Additionally, the proposed method presents a potential strategy for biomarker combination when gold standard information is unavailable, as it derives a composite risk score for the underlying disease status. The method is applied to evaluate different cerebral spinal fluid (CSF) biomarkers for Alzheimer’s disease (AD) detection. The results show that CSF biomarkers hold significant potential for facilitating early AD detection and for continuous disease monitoring. Furthermore, they call attention to biomarker variability in subgroups and reexamination of CSF biomarker distributions. Data used in preparation of this article were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database.

Developing Biomarker Combinations in Multicenter Studies via Direct Maximization and Penalization

Selection and combination of biomarkers using ROC method for disease classification and prediction

Combining Biomarkers to Improve Diagnostic Accuracy in Detecting Diseases With Group‐Tested Data

A distribution-free smoothed combination method of biomarkers to improve diagnostic accuracy in multi-category classification

Combining biomarkers by maximizing the true positive rate for a fixed false positive rate

On the Optimal Combination of Elliptically Distributed Biomarkers to Improve Diagnostic Accuracy

Two-Stage Marker-Stratified Clinical Trial Design in the Presence of Biomarker Misclassification

Likelihood ratio combination of multiple biomarkers via smoothing spline estimated densities

Computation and Selection of Optimal Biomarker Combinations by Integrative ROC Analysis Using CombiROC

Hybrid Design Evaluating New Biomarkers when There is an Existing Screening Test

A Bayesian Platform Trial Design to Simultaneously Evaluate Multiple Drugs in Multiple Indications with Mixed Endpoints.

Adaptive Combination of Randomized and Observational Data

ComPAS: A Bayesian Drug Combination Platform Trial Design with Adaptive Shrinkage

A New Semiparametric Transformation Approach to Disease Diagnosis with Multiple Biomarkers

Boosting the concordance index for survival data - a unified framework to derive and evaluate biomarker combinations

A distribution-free smoothed combination method to improve discrimination accuracy in multi-category classification

A combined efficient design for biomarker data subject to a limit of detection due to measuring instrument sensitivity

Sample size and performance estimation for biomarker combinations based on pilot studies with small sample sizes

A multiple testing framework for diagnostic accuracy studies with co-primary endpoints

Biomarker assessment and combination with differential covariate effects and an unknown gold standard, with an application to alzheimer’s disease

Logistic regression analysis with standardized markers